Physician profile
Duane A Fredericks
NPI 1184618886
$2,834.11
in general payments reported to CMS, 2019-2025
15 companies · $82.47 in 2025
The $82.47 reported for 2025 was less than what a typical Obesity Medicine (Family Medicine) provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $52.99 · 2021: $316 · 2022: $712 · 2023: $758 · 2024: $17.71 · 2025: $82.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,303.92 | 2019-2025 | Wegovy |
| Smith+Nephew, INC. | $440.85 | 2021-2023 | Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.60 | 2023 | Jardiance, Synjardy |
| Asensus Surgical, INC. | $161.59 | 2022-2023 | Senhance |
| Abbvie INC. | $113.83 | 2023 | |
| Currax Pharmaceuticals LLC | $102.18 | 2020-2025 | Contrave |
| Intra-Sana Laboratories | $100.00 | 2022 | |
| Eisai INC. | $93.18 | 2019 | |
| Medtronic, INC. | $67.14 | 2023 | Appose Ulc |
| Vivus LLC | $61.39 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $40.86 | 2019 | |
| Endo Pharmaceuticals INC. | $38.71 | 2019-2020 | |
| Lilly USA, LLC | $19.43 | 2023 | Mounjaro |
| Davol INC. | $18.36 | 2019 | |
| W. L. Gore & Associates, INC. | $18.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Fredericks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.